TVGN logo

TEVOGEN INC

TVGNNASDAQ
🏆 #4668 by market capEarnings Nov 13US Equity
$985.50▲ $74.70 (+7.58%)
Simulated price
🔔
Track TVGN
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.6%
7d▲ 12799.2%
14d▲ 12698.7%
30d▲ 15518.1%
ytd▲ 5836.7%
1y▲ 2413.4%
🏦Market Cap
$29M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
84
Good

Trading Snapshot

Day Range
$975.50 – $997.41
52-Week Range
$3.64 – $40.45
Volume
$3.66B
Avg Volume
$3.80B
Shares Outstanding
4.2M
Next Earnings
Dec 1, 2026

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$843,869
P/E Ratio
-1.2
P/S Ratio
0.0x
EPS (TTM)
$-5.64
Dividend Yield
0.00%
Dilution (1yr)
−6.7%

Why Investors Own TVGN

  • ✓High-growth profile — revenue up +30.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 38% gross margin and 15% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TVGN logo

TEVOGEN INC

TVGN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$26M▼ −51.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$12M▲ +3.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.3M▼ −6.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$3M▼ −$946K YoY
StockOtter · stockotter.space

About TEVOGEN INC

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
84/100

Analyst Ratings

ⓘ
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Aug 2026

Latest News & Updates

🚀
Barron’s·2h ago

TEVOGEN INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift TVGN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

TEVOGEN INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.